Talquetamab, a GPRC5DXCD3 Bispecific Antibody, for Treatment of Relapsed/Refractory Multiple Myeloma in Patients With Prior Exposure to BCMA Targeted Therapies - a "Real World" Study

被引：0
|
作者：
Shkury, Eden [1 ]
Hellou, Tamer [2 ]
Nevo, Lee [2 ]
Avigdor, Abraham [2 ]
Magen, Hila [2 ]
机构：
[1] Sheba Tel HaShomer Med Ctr, Tel Hashomer, Israel
[2] Tel Aviv Univ, Chaim Sheba Med Ctr, Fac Med & Hlth Sci, Tel Aviv, Israel
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-081
引用
收藏
页码：S88 / S89
页数：2
相关论文
共 50 条
  • [31] RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study
    Carlo-Stella, Carmelo
    Mazza, Rita
    Manier, Salomon
    Facon, Thierry
    Yoon, Sung-Soo
    Koh, Youngil
    Harrison, Simon J.
    Er, Jeremy
    Pinto, Antonio
    Volzone, Francesco
    Perrone, Giulia
    Corradini, Paolo
    Cazaubiel, Titouan
    Hulin, Cyrille
    Touzeau, Cyrille
    Moreau, Philippe
    Ocio, Enrique M.
    Gaisan, Carmen Maria Montes
    Popat, Rakesh
    Leong, Sarah
    Offner, Fritz
    Otero, Paula Rodriguez
    Alfonso-Pierola, Ana
    Broeske, Ann-Marie E.
    Dekhtiarenko, Iryna
    Helms, Hans-Joachim
    Belli, Sara
    Rossmann, Eva
    Fauti, Tanja
    Eckmann, Jan
    Moore, Tom
    Schneider, Meike
    Jacob, Wolfgang
    Weisser, Martin
    Hutchings, Martin
    Riley, Caroline Hasselbalch
    BLOOD, 2022, 140
  • [32] Sequencing bispecific antibodies and CAR T cell therapy in multiple myeloma with prior exposure to BCMA-targeted therapies.
    Patel, Urvi
    Oluwole, Olalekan O.
    Kassim, Adetola
    Jayani, Reena
    Belliveau, Paul
    Savani, Bipin
    Dholaria, Bhagirathbhai R.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma
    Shaikh, Hira
    Lochner, Jonathan
    Friend, Reed
    Snyder, Jordan
    Davis, James
    Patrus, Gina
    Dileo, Rachel
    Ahmed, Nausheen
    Mewawalla, Prerna
    Poonsombudlert, Kittika
    Struble, Emily
    Wolcott, Allyson
    Green, Kimberly
    Sparrow, Samantha
    Mushtaq, Muhammad Umair
    Paul, Barry
    Abdallah, Al-Ola
    Strouse, Christopher
    Hashmi, Hamza
    Atrash, Shebli
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S87 - S88
  • [34] Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma
    Raje, Noopur
    Bahlis, Nizar Jacques
    Costello, Caitlin
    Dholaria, Bhagirathbhai
    Solh, Melhem
    Levy, Moshe Yair
    Tomasson, Michael H.
    Damore, Michael A.
    Jiang, Sibo
    Basu, Cynthia
    Skoura, Athanasia
    Chan, Edward M.
    Trudel, Suzanne
    Jakubowiak, Andrzej
    Chu, Michael P.
    Gasparetto, Cristina J.
    Dalovisio, Andrew P.
    Sebag, Michael
    Lesokhin, Alexander M.
    BLOOD, 2022, 140
  • [35] Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: A "real world" experience
    Fucci, Ludovica
    Gensini, Lorenzo
    Coppetelli, Ugo
    La Barbera, Elettra Ortu
    Gentile, Martina
    Fiori, Luciano
    Perrone, Salvatore
    Cimino, Giuseppe
    LEUKEMIA RESEARCH REPORTS, 2022, 17
  • [36] Real-World Safety and Early Efficacy of Talquetamab in Patients with Heavily-Pretreated Relapsed/Refractory Multiple Myeloma
    Costa, Bruno
    Tan, Carlyn
    Shekarkhand, Tala
    Firestone, Ross
    Jurgens, Eric
    Miller, Kevin
    Lesokhin, Alexander
    Shah, Gunjan
    Korde, Neha
    Rajeeve, Sridevi
    Chung, David
    Landau, Heather
    Scordo, Michael
    Hassoun, Hani
    Maclachlan, Kylee
    Shah, Urvi
    Hultcrantz, Malin
    Hamadeh, Issam
    Giralt, Sergio
    Mailankody, Sham
    Usmani, Saad
    Hashmi, Hamza
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S46 - S47
  • [37] Cumulative Incidence and Characteristics of Infections Requiring Treatment, Delay in Treatment Administration or Hospitalisation in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti BCMA or Anti GPRC5D Bispecific Antibodies
    Cellerin, Elise
    Jourdes, Aurelie
    Brousse, Xavier
    Vallet, Nicolas
    Cartau, Tom
    Denis, Blandine
    Harel, Stephanie
    Jamard, Simon
    Redor, Alexis
    Cazaubiel, Titouan
    Roland, Virginie
    Caleteix, Carine
    Charles, Morgane
    Berger, Pierre
    Escure, Guillaume
    Collignon, Aude
    Faure, Emmanuel
    Cazelles, Clarisse
    Lanternier, Fanny
    Vaux, Clementine De La Porte Des
    Frenzel, Laurent
    Blot, Mathieu
    Danion, Francois
    Sonntag, Cecile
    Touzeau, Cyrille
    Pieragostini, Andrea
    Ader, Florence
    Karlin, Lionel
    Macro, Margaret
    Martin-Blondel, Guillaume
    Chalopin, Thomas
    Perrot, Aurore
    BLOOD, 2023, 142
  • [38] Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab
    A. M. G. A. Laheij
    N. W. C. J. van de Donk
    Supportive Care in Cancer, 2024, 32
  • [39] First Results From the RedirecTT-1 Study With Teclistamab (Tec) plus Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
    Cohen, Yael
    Morillo, Daniel
    Gatt, Moshe
    Sebag, Michael
    Kim, Kihyun
    Min, Chang-Ki
    Oriol, Albert
    Ocio, Enrique
    Yoon, Sung-Soo
    Mateos, Maria-Victoria
    Chu, Michael
    Rodriguez-Otero, Paula
    Chu, Michael
    Rodriguez-Otero, Paula
    Avivi, Irit
    Guo, Yue
    Krevvata, Maria
    Peterson, Michelle
    Beelen, Melissa
    Vanak, Jill
    Banerjee, Arnob
    Magen, Hila
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S478 - S479
  • [40] Real-World Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with Teclistamab and Talquetamab; A Multicenter Analysis from the Greek Myeloma Study Group
    Ntanasis-Stathopoulos, Ioannis
    Katodrytou, Eirini
    Hatjiharissi, Evdoxia
    Spanoudakis, Emmanouil
    Douka, Vasiliki
    Fotiou, Despina
    Labropoulou, Vasiliki
    Dalampira, Dimitra
    Spiliopoulou, Vasiliki
    Papadopoulou, Theodosia
    Christoulas, Dimitrios
    Malandrakis, Panagiotis
    Bouchla, Anthi
    Pappa, Vasiliki
    Kastritis, Efstathios
    Terpos, Evangelos
    Dimopoulos, Meletios
    Gavriatopoulou, Maria
    BLOOD, 2024, 144 : 6988 - 6990
12345